Related Experiment Videos
[Progressive multifocal leukoencephalopathy]
J C Wasmuth1, A Wasmuth-Pietzuch, U Spengler
1Universitätsklinik Bonn. j-c.wasmuth@uni-bonn.de
Pathogenesis:
Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system caused by infection and reactivation of JC-virus. About 5% of all HIV-infected patients develop this fatal disease. Although pathogenesis is not completely understood, progressive multifocal leukoencephalopathy is thought to be a persistent infection. The kidneys, bone marrow, peripheral blood lymphocytes and the brain itself are candidates for latency sites of JC-virus. Loss of T-helper-cells in the course of HIV-infection or other immunosuppressive states result in reactivation of JC-virus.
Diagnosis:
Progressive multifocal leukoencephalopathy can be diagnosed by focal neurological symptoms, radiographic signs in magnetic resonance imaging and detection of JC-virus in brain tissue or cerebrospinal fluid.
Treatment:
A specific therapy is not yet available or established. Highly active antiretroviral therapy (HAART) and cidofovir are promising and may prove useful in the near future.
Insights
Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease caused by JC-virus reactivation in immunocompromised individuals, particularly those with HIV. Diagnosis involves neurological symptoms, MRI, and JC-virus detection, with emerging therapies like HAART showing promise.
Area of Science:
- Neurology
- Virology
- Immunology
Context:
- Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system.
- It is caused by the reactivation of the John Cunningham virus (JC-virus).
- PML affects approximately 5% of patients with HIV infection, often proving fatal.
Purpose:
- To summarize the pathogenesis, diagnosis, and current treatment landscape of Progressive Multifocal Leukoencephalopathy (PML).
- To highlight the role of JC-virus reactivation in immunosuppressive states.
Summary:
- JC-virus, a persistent infection, is implicated in PML pathogenesis, with potential latency sites including kidneys, bone marrow, lymphocytes, and the brain.
- Reactivation is triggered by a loss of T-helper cells, common in HIV infection and other immunosuppressive conditions.
- Diagnosis relies on clinical presentation, MRI findings, and detection of JC-virus in cerebrospinal fluid or brain tissue.
- Currently, no definitive therapy exists, but highly active antiretroviral therapy (HAART) and cidofovir show potential.
Impact:
- Improved understanding of PML pathogenesis and JC-virus latency.
- Enhanced diagnostic approaches for PML.
- Identification of promising therapeutic strategies, including HAART and cidofovir, for future clinical application.